- Home
- DJCO vs SYRE Comparison
DJCO vs SYRE Comparison
Compare DJCO & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DJCO
- SYRE
- Stock Information
- Founded
- DJCO 1987
- SYRE 2013
- Country
- DJCO United States
- SYRE United States
- Employees
- DJCO N/A
- SYRE N/A
- Industry
- DJCO Newspapers/Magazines
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- DJCO Consumer Discretionary
- SYRE Health Care
- Exchange
- DJCO Nasdaq
- SYRE Nasdaq
- Market Cap
- DJCO 793.7M
- SYRE 897.9M
- IPO Year
- DJCO N/A
- SYRE 2016
- Fundamental
- Price
- DJCO $377.40
- SYRE $12.67
- Analyst Decision
- DJCO
- SYRE Buy
- Analyst Count
- DJCO 0
- SYRE 8
- Target Price
- DJCO N/A
- SYRE $50.00
- AVG Volume (30 Days)
- DJCO 9.3K
- SYRE 899.5K
- Earning Date
- DJCO 05-13-2025
- SYRE 05-08-2025
- Dividend Yield
- DJCO N/A
- SYRE N/A
- EPS Growth
- DJCO 370.42
- SYRE N/A
- EPS
- DJCO 55.48
- SYRE N/A
- Revenue
- DJCO $71,642,000.00
- SYRE N/A
- Revenue This Year
- DJCO N/A
- SYRE N/A
- Revenue Next Year
- DJCO N/A
- SYRE N/A
- P/E Ratio
- DJCO $6.80
- SYRE N/A
- Revenue Growth
- DJCO 0.34
- SYRE N/A
- 52 Week Low
- DJCO $333.29
- SYRE $10.91
- 52 Week High
- DJCO $602.00
- SYRE $40.49
- Technical
- Relative Strength Index (RSI)
- DJCO 44.77
- SYRE 36.18
- Support Level
- DJCO $359.34
- SYRE $12.04
- Resistance Level
- DJCO $392.76
- SYRE $13.29
- Average True Range (ATR)
- DJCO 16.45
- SYRE 1.27
- MACD
- DJCO 0.32
- SYRE 0.01
- Stochastic Oscillator
- DJCO 31.99
- SYRE 26.02
About DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Journal Technologies segment.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.